Systemic Treatments for Chronic Plaque Psoriasis
JAMA Dermatology has published a review of the pharmacologic landscape on managing adults with moderate to severe plaque psoriasis. Armstrong et al
JAMA Patient Education Page on JAMA Eosinophilic Fasciitis (EF). EF is rare, but begins with swelling and redness of the arms and/or legs. Later the skin thickens and develops the peau d' orange appearance. EF does not involve fingers or toes, & doesnt have Raynauds https://t.co/WEFFITtmQC
Dr. John Cush @RheumNow( View Tweet )
FDA has approved secukinumab (Cosentyx) for use pediatric patients (aged >12yrs) with moderate to severe hidradenitis suppurativa https://t.co/oX4LGU16QP
Dr. John Cush @RheumNow( View Tweet )
FDA Approves Icotrokinra for Plaque Psoriasis
The FDA approved an oral IL-23 inhibitor, icotrokinra (Icotyde), for use in moderate-to-severe plaque psoriasis in adults and children 12 years of age and older who are candidates for systemic therapy or phototherapy, according to a https://t.co/q5b3TceFHx
Dr. John Cush @RheumNow( View Tweet )
Rheumatology Pitfalls (3.20.2026)
Dr. Jack Cush reviews the regulatory actions, news and journal reports from this past week on RheumNow.com.
Read Article
JAMA Patient Education Page on JAMA Eosinophilic Fasciitis (EF). EF is rare, but begins with swelling and redness of the arms and/or legs. Later the skin thickens and develops the peau d' orange appearance. EF does not involve fingers or toes, & doesnt have Raynauds https://t.co/azH9bMRsOb
Dr. John Cush @RheumNow( View Tweet )
FDA Approves Icotrokinra for Plaque Psoriasis
Today the FDA approved an oral IL-23 inhibitor, icotrokinra (Icotyde), for use in moderate-to-severe plaque psoriasis in adults and children 12 years of age and older (who weigh at least 40 kg) who are candidates for systemic therapy or phototherapy.
Read Article
TYK2 Inhibitor Deucravacitinib FDA Approved for Psoriatic Arthritis
On Friday, March 6th, the FDA approved deucravacitinib (Sotyktu) for the treatment of adults with active psoriatic arthritis (PsA) based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials. Deucravacitinib, an oral selective tyrosine kinase 2 (TYK2)
DERM on RheumNow PODCAST (February 2026)
The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, and other CTD skin disorders. dermatology drugs, biologics, JAKs - their use, efficacy, https://t.co/4ub0MeY9vF
Dr. John Cush @RheumNow( View Tweet )
UBER Rheumatology Ride (3.6.2026)
Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com
Read Article
Nice simple overview of SCLERITIS. https://t.co/BOgZK8y4Qq https://t.co/P0dLtA3nKy
Links:
Dr. John Cush @RheumNow( View Tweet )
SATISFACTION (2.27.2026)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Read Article
Paradoxical Reactions, Target Selection & the Future of Imaging in Psoriatic Care
At RheumNow Live, Dr. Joseph Merola presented a compelling discussion on paradoxical immune reactions in psoriatic disease. He began with a case of a 60-year-old woman with mild psoriasis who, https://t.co/AVIOO42vfP
Dr. John Cush @RheumNow( View Tweet )
Referral Rules to Live By (2.20.2026)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Highlights include referral rules, combination biiologics in psoriasis and don't use JAK inhibitors in pregnancy.
Read Article
Paradoxical Reactions, Target Selection & the Future of Imaging in Psoriatic Care
From paradoxical psoriasis to IL-23 vs IL-17 to imaging in PsA, speakers in RheumNow Live's "Decisions in Psoriatic Arthritis" pod delivered valuable, clinically relevant education.
Read Article
Together PSO Trial - Combination Ixekizumab and Tirzepatide
Today Lilly announced top line results of the TOGETHER-PsO open-label, Phase 3b trial demonstrating the significant benefits of concomitant ixekizumab (IXE: an IL-17A inhibitor) and tirzepatide (TIR: GLP-1agonist) over IXE alone.
Read Article
Can I Use JAK Inhibitors During Pregnancy?
In 2020, the ACR Recommendations on Reproductive Health notably avoided firm guidance on the use of JAK inhibitors (JAKi) during pregnancy stating, "There is no available evidence regarding use or safety of the new small- molecule agents, tofacitinib, baricitinib, and apremilast, during
Read Article
RT @ericdeinMD
#RNL26
Paradoxical psoriasis with TNF
Highest in infliximab
Seen highest in IBD, particular Crohn's
Palmopustular is most common manifestation
May have overlap appearance with psoriaform with eczema, histology with psoriaform spongiotic dermatosis with https://t.co/SKQZgbLQUS
Dr. John Cush @RheumNow( View Tweet )
Spectrum of skin Sxs in 518 pts w/ Stills dz from AutoInflammatory Dz Alliance (AIDA) Network Registry dedicated to Still’s disease includes Salmon evanescent rash (64%), macules (7.7%), urticaria (6%), persistent pruritic papules & plaques (PPPP) (4.8%) https://t.co/DW9NoaxNPP https://t.co/U5GrCutYT0
Links:
Dr. John Cush @RheumNow( View Tweet )
RT @Gibson_RheumPAC
Drug-induced SCLE remains an important mimic in biologic-treated patients. Compared with idiopathic SCLE, drug-induced disease is often more widespread and may resolve with antibody normalization after withdrawal.#RNL26 https://t.co/ICOzg3Tz4L
Dr. John Cush @RheumNow( View Tweet )
RT @Gibson_RheumPAC
Important rheumatology signal: dupilumab-associated inflammatory arthritis. Usually seronegative, imaging-supported, and sometimes persistent despite normal labs. Co-management and careful work-up are essential.#RNL26 https://t.co/r73cSZC59s
Dr. John Cush @RheumNow( View Tweet )
RT @@Gibson_RheumPAC
Eczematous eruptions with IL-17 inhibition are increasingly recognized. Registry data suggest higher adjusted incidence with IL-17 inhibitors compared with other biologic classes, especially in older patients and those with atopic history. #RNL26 https://t.co/nvwl5mNg4k
Dr. John Cush @RheumNow( View Tweet )
Maui Potpourri (2.13.2026)
Dr. Jack Cush reviews the hot item takeaways from last week's RheumNow.Live 2026.
- Diet & Obesity Management in Rheumatology - Uzma Haque, MD
- Mitigating risk for Rheum patients undergoing orthopedic surgery - Susan Goodman, MD
- Paradoxical skin reactions – Joseph
Always on exams, but I've never seen a case! JAMA Dermatology reviews Multicentric Reticulohistiocytosis - pt w/ multiple nodules on hands & pain in shoulders, elbows, MCPs, IPs. Erythema over face, chest, & back & bead like Perionychial papules. Rx w/ MTX + Pred https://t.co/QgS5VBOB51
Dr. John Cush @RheumNow( View Tweet )
ANA Pollution (2.06.2026)
Dr. Jack Cush reviews the news, journal articles and regulatory news from this past week on RheumNow.com
Read ArticleRecent Blogs
With their publication in June 2022 (1), the 3rd iteration of the Group for Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment recommendations for Psoriatic Arthritis (PsA) may have set a record or sorts.
Pain is typically ranked by both patients and physicians as the most important symptom of psoriatic arthritis (PsA) to assess and treat. Although the predominant concept of the etiology of pain in PsA is that of inflammation in peripheral joints, entheses, and bone signaling through peripheral nociceptive fibers, perceived as pain in the central nervous system, it is actually more complex than that. The ability of a treatment to ameliorate pain is one of the principle measures of its effectiveness. Thus pain improvement or worsening are key determinants of shared decision making about treatment in PsA.
Read Post
Patient TS was a 30 year old woman who had been living with psoriatic arthritis for about 18 months. Her symptoms had started about 6 months after the birth of her first child with mild psoriasis in her scalp but increasing joint pain in her hands, wrists, elbows, knees, and ankles. She had dactylitis in several fingers that caused her extreme pain.
